Our Approach

Ardelyx develops:

  • Innovative, non-systemic, small molecule therapeutics that work exclusively in the GI tract to treat cardio-renal, GI and metabolic diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas



Reduce systemic uptake, minimize side effects.

Program Indication Research Phase 1 Phase 2 Status Development and Commercial Rights
2a 2b
Tenapanor(NHE3 Inhibitor) ESRD-Pi * *  * *  Phase 2b data in 1Q:2015 AstraZeneca
  • $870mm total potential deal size including $35mm up front and $237.5mm development milestones; tiered royalties
  • AZ funds and is responsible for all R&D
  • Ardelyx has right to co-promote in U.S.
IBS-C *  *  *  *  Phase 2b data announced
Oct 1, 2014
CKD *  *  *  *  Phase 2a data in 2H:2015
RDX002(NaP2b Inhibitor) ESRD-Pi *  *  *  *  Research SANOFI
  • $198mm total potential deal size; tiered royalties
  • Sanofi funds and is responsible for all R&D
  • Ardelyx has right to co-promote in United States
RDX009(TGR5 agonist) IBD *  *  *  *  Research Ardelyx
RDX013(K+ channel modulator) Hyper-
kalemia
*  *  *  *  Research Ardelyx
RDX020 (Cl- channel modulator) Fluid
Overload
*  *  *  *  Research Ardelyx
Undisclosed
Programs
N/A *  *  *  *  Research Ardelyx